(5Z,8Z,11Z,14Z)-N-(3,4-dihydroxyphenethyl)icosa-5,8,11,14-tetraenamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (5Z,8Z,11Z,14Z)-N-(3,4-dihydroxyphenethyl)icosa-5,8,11,14-tetraenamide
• 英文别名: N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide
• 化学式: C₂₈H₄₁NO₃
• 分子量: 439.6
• InChiKey: MVVPIAAVGAWJNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  32
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives
  申请人：Palin Ronald

  公开号：US20070112034A1

  公开（公告）日：2007-05-17

  The invention relates to 2-(benzimidazol-1-yl)-acetamide bisaryl derivative having the general Formula I wherein n is 0 or 1; Ar 1 represents a diradical derived from a 5- or-6-membered aromatic ring, optionally comprising 1-3 heteroatoms selected from N, O and S, said ring being optionally substituted with (C 1-4 )alkyl, (C 1-4 )alkyloxy, halogen, CF 3 or cyano; Ar 2 represents a 6-membered aryl ring, optionally comprising 1-3 nitrogen atoms, said ring being optionally substituted with 1-3 substituents selected from (C 1-4 )alkyl (optionally substituted with 1 or more halogens), (C 1-4 )alkyloxy (optionally substituted with 1 or more halogens), di(C 1-4 )alkylamino, halogen, CF 3 or cyano; or a pharmaceutically acceptable salt thereof; to pharmaceutical compositions comprising the same and to the use of said 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives in the treatment of TRPV1 mediated disorders.

  本发明涉及具有通式I的2-(苯并咪唑-1-基)-乙酰胺双芳基衍生物 其中n为0或1；Ar 1 代表来自5或6元芳环的二自由基，可选地包含1-3个选自N、O和S的杂原子，所述环可选地被(C 1-4 )烷基、(C 1-4 )烷氧基、卤素、CF 3 或腈基取代；Ar 2 代表一个6元芳环，可选地包含1-3个氮原子，所述环可选地被1-3个选自( C 1-4 )烷基(可选地被1个或更多卤素取代)、(C 1-4 )烷氧基(可选地被1个或更多卤素取代)、二(C 1-4 )烷基氨基、卤素、CF 3 或腈基的取代基取代；或其药用盐；涉及含有该化合物的药物组合物，以及使用该2-(苯并咪唑-1-基)-乙酰胺双芳基衍生物治疗TRPV1介导的疾病。
• Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20050215575A1

  公开（公告）日：2005-09-29

  Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了(7-吡啶基-4-苯基氨基喹唑啉-2-基)-甲醇类似物。这些化合物是配体，可用于调节体内或体外特定受体的活性，并在治疗与人类、驯养伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。提供了用于治疗这些疾病的药物组合物和使用它们的方法，以及用于受体定位研究的这种配体的方法。
• [EN] 5-PHENYL-ISOXAZOLE-3-CARBOXAMIDE DERIVATIVES AS TRPV1 MODULATORS<br/>[FR] DÉRIVÉS D'ISOXAZOLE-3-CARBOXAMIDE
  申请人：ORGANON NV

  公开号：WO2009016241A1

  公开（公告）日：2009-02-05

  The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.

  本发明涉及具有通式（I）的异噁唑-3-羧酰胺衍生物，或其药学上可接受的盐，包括含有相同成分的药物组合物，以及所述异噁唑-3-羧酰胺衍生物用于治疗TRPV1介导的疾病，如急性和慢性疼痛疾病、急性和慢性神经病性疼痛、急性和慢性炎症性疼痛、呼吸道疾病和下尿路疾病。
• [EN] ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES<br/>[FR] ANALOGUES QUINAZOLINE A SUBSTITUTION D'ARYLALKYLAMINO
  申请人：NEUROGEN CORP

  公开号：WO2005087227A1

  公开（公告）日：2005-09-22

  Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了芳基烷基氨基取代的喹唑啉类似物，其化学式如下，其中变量如本文所述。这些化合物是配体，可用于体内或体外调节特定受体活性，并在治疗人类、驯养伴侣动物和家畜动物中与病理性受体激活相关的疾病方面特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于受体定位研究的这类配体的方法。
• [EN] 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE QUINAZOLIN-4-YLAMINE 2-SUBSTITUEE COMME MODULATEURS DES RECEPTEURS DE LA CAPSICINE
  申请人：NEUROGEN CORP

  公开号：WO2004055003A1

  公开（公告）日：2004-07-01

  Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了某些2-取代的喹唑啉-4-胺类似物。这些化合物是配体，可用于调节体内或体外特定受体的活性，并且在治疗与人类、驯养伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。还提供了用于治疗此类疾病的药物组合物和使用它们的方法，以及用于受体定位研究的配体使用方法。